Medicare IPPS and MS-DRGs for Medical Devices: Inpatient Payment Guide
Guide to Medicare IPPS and MS-DRGs for medical devices, covering inpatient payment calculation, NTAP add-on payments, and the FY2027 Breakthrough overhaul.
Why IPPS and MS-DRG Economics Determine Inpatient Device Adoption
For medical device manufacturers developing novel hospital inpatient technologies—such as transcatheter heart valves, spinal fusion implants, neurostimulation systems, structural heart repair devices, or surgical robotics—securing FDA clearance or approval is only the first hurdle. The ultimate driver of commercial adoption and market penetration is hospital economics.
When a Medicare beneficiary is admitted to an acute-care hospital for a procedure involving a medical device, Medicare does not pay the hospital line-by-line for the device's purchase price. Instead, Medicare pays a fixed, bundled prospective rate under the Inpatient Prospective Payment System (IPPS), determined by the patient's assigned Medicare Severity Diagnosis-Related Group (MS-DRG).
If the assigned MS-DRG payment is generous relative to hospital costs, clinical adoption faces minimal financial friction. However, if a new high-cost medical device is introduced into an existing MS-DRG whose fixed payment rate was established based on older, cheaper technology, the hospital faces a direct financial loss on every single case. Without supplemental reimbursement, hospital value analysis committees (VACs) will routinely block physician requests to adopt the technology—regardless of its clinical benefits.
To bridge this financial gap during early commercialization, CMS created the New Technology Add-on Payment (NTAP) program under 42 CFR §§ 412.87–412.88. NTAP provides temporary incremental payments above the base DRG rate for qualifying new devices for two to three years while hospital cost data catches up.
Crucially, the inpatient reimbursement landscape is undergoing a massive policy overhaul. In the FY2027 IPPS Proposed Rule (released April 2026), CMS proposed a transformative policy shift: eliminating the alternative NTAP pathway for Breakthrough Devices—and a parallel alternative pathway for OPPS transitional pass-through—beginning with FY2028 NTAP applications. The pass-through program itself is not repealed; instead, Breakthrough Devices would have to satisfy the same rigorous cost and substantial clinical improvement criteria required under the traditional pathway.
This guide provides market access, reimbursement, and commercial executives with an in-depth analysis of IPPS and MS-DRG mechanics: how inpatient device cases are coded and assigned to DRGs, how relative weights and hospital-specific adjustments determine final payment, how NTAP supplements base rates, the FY2026 final rule parameters, and strategic guidance for navigating the FY2027 Breakthrough-pathway elimination.
How the Inpatient Prospective Payment System (IPPS) Works
Statutory Authority and Framework
The Inpatient Prospective Payment System was established by Congress under Section 1886(d) of the Social Security Act to control Medicare Part A inpatient hospital expenditures. Operating on a fiscal-year cycle (October 1 through September 30), IPPS sets prospective per-discharge payment rates for roughly 3,100 acute-care hospitals across the United States.
Under IPPS, hospital payments are built on a multi-step formula that transforms clinical coding into a dollar amount:
[ICD-10-CM Diagnosis & ICD-10-PCS Procedure Codes]
|
v
[MS-DRG Grouper Classification (~766 - 770 DRGs)]
|
v
[DRG Relative Weight] X [Standardized Base Rate]
|
v
[Geographic Wage Index & Hospital Adjustments (DSH, IME, Outlier)]
|
v
[Final Medicare Hospital Payment]
The Step-by-Step Payment Calculation Formula
To understand whether your device's inpatient procedure will be financially viable for a hospital, you must understand how CMS calculates the baseline payment:
$$\text{Base Payment} = \text{MS-DRG Relative Weight} \times \left[ (\text{Labor Share} \times \text{Wage Index}) + \text{Non-Labor Share} \right]$$
- ICD-10 Coding: When a patient is discharged, the hospital submits a claim containing ICD-10-CM diagnosis codes (principal and secondary) and ICD-10-PCS procedure codes detailing surgical interventions and device implantations.
- MS-DRG Grouper Assignment: CMS software (the "Grouper") processes these codes, placing the case into one of approximately 766 payable MS-DRGs (for FY2027; 770 for FY2026).
- Relative Weight: Each MS-DRG carries a relative weight assigned by CMS reflecting the national average hospital resource consumption for cases in that group relative to the average case (weight of 1.0000). For example, a minor procedure might carry a weight of 0.8500, while a complex open heart surgery with a mechanical heart assist device might carry a weight exceeding 10.0000.
- Standardized Amount: The relative weight is multiplied by a national standardized payment amount (composed of operating and capital standardized amounts), split into labor-related and non-labor-related shares.
- Hospital-Specific Adjustments:
- Area Wage Index: Adjusts the labor-related share for regional labor cost variations (e.g., San Francisco vs. rural Mississippi).
- Disproportionate Share Hospital (DSH) / Uncompensated Care: Additional payments for hospitals treating high proportions of low-income patients.
- Indirect Medical Education (IME): Add-on payments for teaching hospitals training resident physicians.
- High-Cost Outliers: Supplemental payments triggered when a hospital's estimated cost for an extraordinarily expensive case exceeds the MS-DRG payment plus a fixed-loss threshold ($40,397 for FY2026, down from $46,217 in FY2025).
How CMS Recalibrates MS-DRG Weights Using HCRIS Hospital Cost Data
Understanding how DRG relative weights are recalibrated annually is essential for long-term device commercial planning. CMS recalibrates relative weights using hospital cost and charge data reported in the Healthcare Cost Report Information System (HCRIS) database.
The Cost-to-Charge Ratio (CCR) Conversion Mechanics
Hospitals report billed charges on Medicare UB-04 claims. However, billed charges do not reflect actual hospital costs. To convert billed charges into estimated costs for DRG weight setting, CMS calculates departmental Cost-to-Charge Ratios (CCRs) from hospital cost reports:
$$\text{Estimated Case Cost} = \sum \left( \text{Departmental Billed Charge} \times \text{Departmental CCR} \right)$$
+-----------------------------------------------------------------------------------+
| HOW DEVICE COSTS IMPACT DRG WEIGHT RECALIBRATION |
+-----------------------------------------------------------------------------------+
| Year 1: Device Launches at Commercial Price ($25,000) |
| Hospitals bill the device under Revenue Center 0278 (Medical Supplies). |
| |
| Year 2: HCRIS Data Collection |
| CMS collects MedPAR claims and matches them with hospital CCRs. |
| |
| Year 3 - 4: Annual IPPS Rulemaking Recalibration |
| CMS aggregates case costs nationwide for the assigned MS-DRG. |
| If average case costs increased significantly, CMS increases the DRG |
| relative weight in the next fiscal year rule. |
+-----------------------------------------------------------------------------------+
Because this recalibration process takes 2 to 3 years from commercial launch to appear in published DRG relative weights, innovative devices face a severe negative margin during their initial market entry phase. This 2-to-3-year structural lag is precisely why NTAP was created by Congress.
The Two-Midnight Rule: Determining Inpatient (IPPS) vs. Outpatient (OPPS) Coverage
A critical operational challenge for medical device manufacturers is navigating whether a hospital procedure is classified as an inpatient stay under IPPS or an outpatient observation case under OPPS.
The CMS Two-Midnight Benchmark (42 CFR § 412.3)
Under Medicare's Two-Midnight Rule, an admission is generally appropriate for Medicare Part A IPPS payment if the admitting physician expects the patient to require hospital care spanning at least two midnights:
- Inpatient Admission (IPPS): Expectation of $\ge 2$ midnights of hospital care. Payment is made via MS-DRG (eligible for NTAP).
- Outpatient Observation (OPPS): Expectation of $< 2$ midnights. Payment is made via Ambulatory Payment Classifications (APCs), eligible for OPPS Transitional Pass-Through (C-codes), not NTAP.
- Inpatient Only (IPO) List: CMS maintains a specific list of high-risk surgical procedures that Medicare will only reimburse under IPPS, regardless of expected length of stay. If your device's primary surgical procedure is on the IPO list, all Medicare cases will be processed under IPPS.
+----------------------------------------------+
| PHYSICIAN ADMISSION DECISION |
+----------------------------------------------+
|
+----------------------------+----------------------------+
| |
v v
+-----------------------+ +-----------------------+
| Expectation >= 2 | | Expectation < 2 |
| Midnights | | Midnights |
+-----------------------+ +-----------------------+
| Reimbursed via IPPS | | Reimbursed via OPPS |
| MS-DRG Base Payment | | APC Group Payment |
| Eligible for NTAP | | Eligible for Pass-Thru|
+-----------------------+ +-----------------------+
Hospital Readmission Reduction Program (HRRP) and Quality Penalties
In addition to base MS-DRG payments, hospital reimbursement under IPPS is modified by statutory quality performance programs established under the Affordable Care Act:
1. Hospital Readmission Reduction Program (HRRP) (§ 1886(q))
CMS reduces overall IPPS payments by up to 3.0 percent for hospitals experiencing excess 30-day readmissions across six key clinical conditions: acute myocardial infarction (AMI), heart failure (HF), pneumonia, chronic obstructive pulmonary disease (COPD), elective primary total hip/knee arthroplasty (THA/TKA), and coronary artery bypass graft (CABG).
Device Value Proposition: If a novel implantable device (such as a remote hemodynamic monitor or advanced heart failure sensor) reduces 30-day hospital readmissions, device manufacturers can build health economic models demonstrating that the device protects the hospital from multi-million-dollar HRRP penalties across its total Medicare volume.
2. Hospital Value-Based Purchasing (VBP) Program (§ 1886(o))
CMS withholds 2.0 percent of base DRG payments from all participating IPPS hospitals, redistributing those funds as incentive payments based on performance across four domain pillars: Person and Community Engagement, Clinical Care, Safety, and Efficiency and Cost Reduction.
MS-DRG Classification Logic: Severity Tiers and Device-Dependent Groups
MS-DRGs are structured hierarchically around Major Diagnostic Categories (MDCs), reflecting primary organ systems. Within each clinical category, cases are divided into surgical vs. medical interventions, and then split into severity tiers based on secondary diagnoses:
- MCC: Major Complication or Comorbidity (highest resource intensity)
- CC: Complication or Comorbidity (moderate resource intensity)
- Without CC/MCC: Uncomplicated cases (lowest resource intensity)
Severity Tier Payment Spreads: A Cardiovascular Example
The impact of severity tiers on hospital reimbursement is substantial. Consider the MS-DRG structure for percutaneous coronary interventions (PCI) with intraluminal device insertion:
| MS-DRG | Title / Severity Level | Relative Weight (Approx.) | Estimated National Payment |
|---|---|---|---|
| MS-DRG 359 | Percutaneous Coronary Atherectomy w/ Intraluminal Device w/ MCC (new FY2026) | 3.1500 | ~$22,500 |
| MS-DRG 360 | Percutaneous Coronary Atherectomy w/ Intraluminal Device w/o MCC (new FY2026) | 2.1000 | ~$15,000 |
If a novel coronary stent or atherectomy device costs $4,500 per unit, that cost represents 20% of the hospital's total reimbursement in an MCC case (MS-DRG 359), but 30% of total reimbursement in a non-MCC case (MS-DRG 360). Hospital financial managers carefully evaluate these margins when making technology acquisition decisions.
Device-Dependent DRGs and Replaced Device Credits
Certain MS-DRGs are explicitly defined by the presence of a specific implantable device (e.g., cardiac pacemakers, ICDs, joint replacements, endovascular grafts, mechanical circulatory support). In these device-dependent DRGs, procedural coding under ICD-10-PCS directly determines DRG assignment.
CMS maintains a strict Replaced Device Credit Policy. Under IPPS regulations, if a hospital receives a free replacement device or a credit from the device manufacturer equal to 50% or more of the cost of a replaced device (due to warranty, recall, or trial credit), the hospital must report specific condition codes (Condition Code 49 or 50) on the Medicare claim. CMS then reduces the MS-DRG payment by the exact amount of the credit to prevent double payment.
Bridging the Payment Gap: The New Technology Add-On Payment (NTAP)
When a groundbreaking medical device enters the market, historical hospital cost data does not yet reflect its purchase price. Because MS-DRG relative weights are recalibrated annually using hospital cost report data that is 2 to 3 years old, new devices face a systematic reimbursement lag.
To solve this problem, Congress established the New Technology Add-on Payment (NTAP) under Sections 1886(d)(5)(K) and (L) of the Social Security Act, codified at 42 CFR §§ 412.87 and 412.88.
NTAP Eligibility Criteria: Traditional vs. Alternative Pathway
To qualify for NTAP under the Traditional Pathway, a device sponsor must satisfy three statutory criteria:
+-------------------------------------------------+
| TRADITIONAL NTAP THREE-CRITERIA GATE |
+-------------------------------------------------+
|
+---------------------------------+---------------------------------+
| | |
v v v
+------------------+ +------------------+ +------------------+
| 1. NEWNESS | | 2. COST | | 3. SUBSTANTIAL |
| CRITERION | | CRITERION | | CLINICAL IMP. |
+------------------+ +------------------+ +------------------+
| FDA clearance / | | Average case cost| | Must prove |
| approval within | | exceeds CMS cost | | significant |
| 2-3 years of | | threshold for | | clinical benefit |
| application date | | assigned DRG | | over existing tech|
+------------------+ +------------------+ +------------------+
- Newness Criterion: The technology must be within 2 to 3 years of initial FDA commercial authorization (or initial market availability) at the start of the fiscal year for which NTAP is requested.
- Cost Criterion: The average charge for inpatient cases involving the new technology must exceed a specified cost threshold established annually by CMS for the assigned MS-DRG.
- Substantial Clinical Improvement Criterion: The applicant must demonstrate through robust clinical evidence that the technology provides a substantial clinical improvement over existing therapeutic or diagnostic options (e.g., significant reduction in mortality, morbidity, readmissions, or operating room time).
The Alternative Pathway (Breakthrough & Antimicrobial Devices)
Historically, CMS established an Alternative Pathway for devices granted FDA Breakthrough Device designation or Qualified Infectious Disease Product (QIDP) status. Under this alternative pathway, Breakthrough Devices were exempt from proving substantial clinical improvement—they only had to meet the newness and cost criteria to receive NTAP approval.
The NTAP Payment Formula
NTAP does not replace the MS-DRG payment; it is an incremental add-on payment calculated on a case-by-case basis. Under 42 CFR § 412.88(a)(2), the add-on payment is set at:
$$\text{NTAP Payment} = \min \left( 65% \times \text{Device Cost}, \quad 65% \times \left[ \text{Total Case Cost} - \text{Base MS-DRG Payment} \right] \right)$$
NTAP Payment Calculation Example
+-----------------------------------------------------------------------------------+
| Base MS-DRG Payment: $18,000 |
| Device Purchase Price: $12,000 |
| Total Hospital Case Cost: $28,000 |
| Excess Case Cost ($28,000 - $18,000): $10,000 |
| |
| Calculation 1: 65% of Device Cost (65% of $12,000) = $7,800 |
| Calculation 2: 65% of Excess Cost (65% of $10,000) = $6,500 |
| |
| Final NTAP Add-on Payment (Lesser of Calc 1 and Calc 2): $6,500 |
| Total Hospital Reimbursement ($18,000 Base + $6,500 NTAP): $24,500 |
+-----------------------------------------------------------------------------------+
FY2026 IPPS Final Rule Highlights (CMS-1833-F)
The FY2026 IPPS Final Rule (CMS-1833-F; Federal Register doc. 2025-14681, published August 4, 2025; effective October 1, 2025) established the current operational parameters for inpatient hospital payment:
- Operating Rate Update: Net operating payment rates increased by 2.6 percent for hospitals participating in the Inpatient Quality Reporting (IQR) program and achieving meaningful use of EHR technology (reflecting a 3.3% market basket update minus a 0.7 percentage point productivity adjustment).
- Approved NTAP Technologies: CMS approved 54 total technologies for NTAP status in FY2026 (27 continuing, 5 traditional pathway, and 22 alternative pathway), resulting in an estimated $192 million in supplemental inpatient payments.
- New MS-DRG Classifications:
- MS-DRG 209: Created for complex aortic arch procedures.
- MS-DRG 213: Created for endovascular abdominal aorta and iliac branch procedures.
- MS-DRG 318: Created for percutaneous coronary atherectomy without intraluminal device.
- MS-DRGs 359/360: Created for percutaneous coronary atherectomy with intraluminal device.
Named FY2026 Device NTAP Maximum Payment Benchmark Table
| Technology / Device Name | Manufacturer | Clinical Indication / Category | FY2026 Max NTAP Payment |
|---|---|---|---|
| EVOQUE Tricuspid Valve | Edwards Lifesciences | Transcatheter tricuspid valve replacement | $31,850.00 |
| TriClip G4 System | Abbott Structural Heart | Transcatheter tricuspid valve repair | $26,000.00 |
| EUROPA System | Spine Wave | Posterior cervical fusion system | $80,548.00 |
| WiSE CRT System | EBR Systems | Wireless endocardial CRT stimulation | $41,145.00 |
| Aveir DR Leadless Pacer | Abbott Medical | Dual-chamber leadless pacemaker system | $15,600.00 |
| Minima Stent System | Interventional Medical | Pediatric vascular stent system | $22,685.00 |
| aprevo-C Interbody | Carlisle Medical | Patient-specific cervical fusion device | $21,125.00 |
| 4WEB ATS Structural Spine | 4WEB Medical | Truss-system interbody spine implant | $15,275.00 |
| iFuse TORQ TNT | SI-BONE | Sacroiliac joint fusion implant | $3,960.45 |
FY2027 IPPS Proposed Rule: The Breakthrough-Pathway Overhaul
In April 2026, CMS published the FY2027 IPPS Proposed Rule (Federal Register doc. 2026-07203, published April 14, 2026). While the rule proposes a standard 2.4 percent payment rate update (totaling ~$1.9 billion in additional hospital payments across 766 payable MS-DRGs, versus 770 for FY2026), its most seismic policy proposal targets device innovation pathways.
+-----------------------------------------------------------------------+
| FY2027 CMS REIMBURSEMENT PATHWAY OVERHAUL PROPOSAL |
+-----------------------------------------------------------------------+
|
+------------------------+------------------------+
| |
v v
+---------------------------+ +---------------------------+
| Inpatient NTAP Program | | Outpatient OPPS Program |
+---------------------------+ +---------------------------+
| PROPOSED: End alternative | | PROPOSED: End alternative |
| Breakthrough pathway from | | Breakthrough pathway for |
| FY2028 NTAP applications | | pass-through (apps on/ |
| | | after Oct 1, 2026) |
+---------------------------+ +---------------------------+
| |
+------------------------+------------------------+
|
v
+-----------------------------------------------+
| IMPLICATION FOR BREAKTHROUGH DEVICE SPONSORS |
+-----------------------------------------------+
| - Must prove Substantial Clinical Improvement |
| - Must satisfy Traditional DRG Cost Threshold |
| - Must build comparative clinical trials early|
+-----------------------------------------------+
The Proposal to Eliminate the Breakthrough Alternative NTAP Pathway
Under the proposed rule, CMS intends to discontinue the alternative pathway for NTAP (covering FDA Breakthrough Devices, QIDP, and LPAD products) for FY2028 applications and beyond, and to discontinue the alternative pathway for OPPS device transitional pass-through for applications received on or after October 1, 2026. The pass-through program itself is not eliminated: existing approved device category codes continue for their standard two- to three-year term, and Breakthrough devices may still earn pass-through by independently meeting the traditional substantial-clinical-improvement standard under § 419.66(c)(2)(i). For our detailed analysis of the repeal's commercialization impact and the parallel CMS-FDA RAPID coverage pathway, see CMS NTAP Repeal for Breakthrough Devices: FY 2027 IPPS Impact.
CMS Rationale
CMS argues that the Breakthrough designation by FDA reflects a premarket regulatory status based on early potential, whereas Medicare payment policy requires empirical evidence that a technology improves clinical outcomes for Medicare beneficiaries before granting supplemental taxpayer-funded add-on payments.
Key Implications for Device Manufacturers
If finalized as proposed:
- End of Automatic Exemption: Breakthrough Devices will no longer receive an automatic pass on the substantial clinical improvement criterion.
- Standard Evidentiary Burden: Breakthrough Device sponsors must generate rigorous comparative clinical data (e.g., randomized controlled trials or high-quality real-world evidence) proving superior clinical outcomes over existing SOC technologies to win NTAP approval.
- Loss of Dual Accelerated Pathways: Because CMS is simultaneously proposing to eliminate the OPPS transitional pass-through alternative pathway for outpatient devices, Breakthrough designation will no longer provide a shortcut to accelerated reimbursement in either the inpatient or outpatient care setting.
Detailed FY2027 MS-DRG Restructuring Proposals
In addition to the Breakthrough pathway overhaul, the FY2027 IPPS Proposed Rule contains specific MS-DRG reclassifications that directly impact cardiovascular, orthopedic, and neurological device manufacturers:
1. Spinal Fusion and Disc Arthroplasty Restructuring (MS-DRGs 210 & 211)
CMS proposes to split cervical spinal fusion procedures into distinct MS-DRGs based on the presence of motion-sparing disc arthroplasty versus static interbody fusion devices. This split aims to better reflect the higher initial acquisition cost of multi-level cervical disc prostheses.
2. Leadless Pacemaker and CRT Adjustments (MS-DRGs 523, 524, & 525)
Following the expiration of NTAP status for dual-chamber leadless pacemakers (e.g., Abbott Aveir DR), CMS proposes establishing permanent dedicated MS-DRG weights for leadless cardiac pacemakers to incorporate historical device costs into baseline hospital reimbursement.
3. Endovascular Vascular Repair Restructuring (MS-DRGs 449 & 400)
CMS proposes refining procedure code combinations for complex branched endovascular aortic repair (BEVAR) and fenestrated endovascular repair (FEVAR), shifting these high-cost graft procedures into higher-weighted surgical DRGs.
How Hospital Value Analysis Committees (VACs) Evaluate Inpatient Device Economics
Medical device commercialization teams often fail to realize that winning over surgeons or interventionalists is only half the battle. Hospital Value Analysis Committees (VACs) evaluate every new inpatient device using a strict financial framework anchored in IPPS mechanics:
+-----------------------------------------------------------------------------------+
| HOSPITAL VALUE ANALYSIS COMMITTEE (VAC) EVALUATION FLOW |
+-----------------------------------------------------------------------------------+
| 1. DRG Mapping & Baseline Payment Verification |
| Which MS-DRG will capture this procedure, and what is our hospital's specific |
| blended base payment (including wage index, DSH, and IME)? |
| |
| 2. Incremental Device Acquisition Cost Analysis |
| What is the net price of the new device compared to the existing standard-of- |
| care implant currently utilized in our operating rooms? |
| |
| 3. Contribution Margin Impact |
| Will adopting this device erode the hospital's per-case contribution margin, |
| or does NTAP / length-of-stay reduction offset the price premium? |
| |
| 4. Outlier & Post-Acute Risk Assessment |
| Does the procedure cross the high-cost outlier threshold, or reduce 30-day |
| readmission penalties under the Hospital Readmissions Reduction Program (HRRP)?|
+-----------------------------------------------------------------------------------+
Strategic Recommendations for Device Manufacturers
- Conduct Early DRG Mapping: Map your device's clinical procedure to candidate ICD-10-PCS codes at least 24 months prior to FDA submission. Determine whether the expected MS-DRG relative weight provides positive hospital contribution margins.
- Prepare for Post-Breakthrough NTAP Submissions: If your device holds Breakthrough status and will launch in FY2028 or later, do not rely on the alternative pathway exemption. Design pivotal IDE trials to include prospective comparative endpoints (e.g., mortality, complications, readmissions, OR time) required to satisfy the Traditional Pathway substantial clinical improvement hurdle.
- Equip Field Teams with Hospital-Specific Calculator Tools: Provide health economics and outcomes research (HEOR) calculators that allow hospital VACs to model net contribution margins incorporating local wage-index adjustments and NTAP add-on payments.
Strategic Reimbursement Matrix: Inpatient vs. Outpatient vs. Bundled Models
Medical device commercial leaders must view IPPS within the broader context of Medicare payment programs. The table below illustrates how IPPS compares with outpatient payment and bundled care models:
| Payment Program | Care Setting | Primary Coding Driver | Payment Mechanics | Device Add-On Mechanism |
|---|---|---|---|---|
| Medicare IPPS | Inpatient Hospital | ICD-10-CM / ICD-10-PCS -> MS-DRG | Bundled per-discharge prospective payment based on relative weight | NTAP (Add-on up to 65% of device/excess cost; 42 CFR § 412.88) |
| Medicare OPPS | Outpatient Hospital | CPT / HCPCS -> APC | Prospective payment per Ambulatory Payment Classification | Transitional Pass-Through (C-codes; add-on payment for 2-3 years) |
| Bundled Payments (BPCI-A / TEAM / CJR) | Inpatient & Post-Acute Episode | MS-DRG Anchor | Target price set for 30- to 90-day episode of care; target reconciled against actual spend | None. Devices must demonstrate total episode cost reduction to be attractive |
Frequently Asked Questions (FAQ)
What is the difference between an MS-DRG and an NTAP payment?
An MS-DRG is the primary, bundled prospective payment that Medicare pays a hospital for an entire inpatient stay based on the patient's diagnosis and procedures. NTAP is a temporary, supplemental add-on payment paid on top of the base MS-DRG rate for qualifying new technologies whose costs exceed the baseline DRG payment threshold.
How does the MS-DRG grouper assign my device's case, and can I influence it?
The MS-DRG grouper assigns cases based on the ICD-10-PCS procedure codes and ICD-10-CM diagnosis codes reported on the hospital claim. Device manufacturers can influence DRG assignment by applying to the CMS ICD-10 Coordination and Maintenance Committee for a new, specific ICD-10-PCS procedure code that uniquely identifies their device procedure.
Does a Breakthrough Device automatically get NTAP, and will that change in FY2028?
Through FY2027, FDA Breakthrough Devices qualify for the NTAP Alternative Pathway, meaning they are exempt from proving substantial clinical improvement (they still must meet newness and cost criteria). However, under the FY2027 IPPS Proposed Rule, CMS plans to eliminate this alternative pathway starting in FY2028, requiring Breakthrough devices to satisfy all three traditional criteria.
How does the IPPS/MS-DRG interact with OPPS pass-through and bundled payments?
IPPS governs inpatient hospital admissions. OPPS governs outpatient hospital procedures. If a device procedure shifts from inpatient to outpatient, reimbursement shifts from MS-DRGs (with NTAP) to APCs (with OPPS Transitional Pass-Through). Under bundled payment models (like BPCI Advanced or TEAM), hospitals receive a target price anchored on the MS-DRG, making device cost-effectiveness over the entire 30- to 90-day episode critical.
Related Guides and Resources
For further analysis of Medicare reimbursement, coding, and market access strategies, explore our related guides:
- CMS NTAP Repeal for Breakthrough Devices — Deep analysis of the FY2027 alternative-pathway repeal, RAPID coverage, and commercialization impact.
- NTAP Application Guide for Medical Devices — Comprehensive criteria, application timeline, and MEARIS submission strategies.
- Medicare OPPS Transitional Pass-Through Guide — Outpatient device add-on payments under C-codes and APCs.
- Bundled Payments for Medical Devices — Navigating BPCI Advanced, CJR, and the TEAM episode payment models.
- CMS-FDA RAPID Coverage Pathway Guide — Accelerated coverage initiatives for Breakthrough Devices.
- CPT, HCPCS, and ICD Coding Strategy Guide — Establishing procedure and billing codes to drive hospital DRG assignment.